Study guide
4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment
ASCP Hematology Technologist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Hematopoiesis & Cellular Physiology
1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis
2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias
2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias
3 Chapter 3: Hemolytic Anemias & Erythrocytosis
3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification
4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation
4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment
5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms
5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies
6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems
6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia
7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation
7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays
8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics
8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis
9 Chapter 9: Laboratory Operations, Quality Assessment & Safety
9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges
4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment
Key Takeaways Explain This Topic AI
Bone marrow evaluation combines aspirates (high-resolution cytomorphology, differential counts, cytochemistry, flow cytometry) and core biopsies (overall cellularity, tissue architecture, fibrosis, granulomas, metastatic nests).
A 'dry tap' (punctio sicca) occurs in myelofibrosis, hairy cell leukemia, and hypercellular packed marrow; touch imprints (roll preps) of the un-decalcified core biopsy are vital for morphologic evaluation.
The normal adult Myeloid-to-Erythroid (M:E) ratio is 1.5:1 to 3.0:1 (up to 4:1); calculations include all granulocytic precursors in the numerator and all nucleated erythroid stages in the denominator while strictly excluding lymphocytes, plasma cells, and monocytes.
Elevated M:E ratios (>4:1) indicate myeloid hyperplasia (infections, CML) or erythroid hypoplasia (pure red cell aplasia); decreased M:E ratios (<1.5:1) indicate erythroid hyperplasia (hemolytic/megaloblastic anemias) or myeloid hypoplasia (agranulocytosis).
Prussian blue staining quantifies macrophage hemosiderin storage (graded 0 to 4+) and identifies sideroblasts (30–50% normal sideroblasts vs ring sideroblasts with ≥5 iron granules encircling ≥1/3 of the nucleus in MDS-RS).
Last updated: August 2026
Bone Marrow Examination, Differential & M:E Ratio Assessment
Bone marrow evaluation is an indispensable diagnostic procedure in hematology that provides direct assessment of hematopoietic cellularity, lineage maturation, storage iron reserves, and structural architecture. Comprehensive evaluation integrates clinical findings with peripheral blood counts, aspirate cytomorphology, core biopsy histology, cytochemical stains, flow cytometry, cytogenetics, and molecular testing. BONE MARROW EVALUATION
- │
- ┌───────────────────────┴───────────────────────┐
- ▼ ▼
- SPECIMEN COMPONENTS & KINETICS QUANTITATIVE PARAMETERS
- Posterior Superior Iliac Spine (PSIS) • Cellularity Formula: (100 - Age) ± 10%
- Aspirate: Cytomorphology, 500-cell diff • 500-Cell Aspirate Differential Count
- Core Biopsy: Architecture, cellularity, • Myeloid-to-Erythroid (M:E) Ratio:
- fibrosis (WHO MF 0–3) - Normal: 1.5:1 to 3.0:1 (up to 4:1)
- Touch Imprints: Critical in "Dry Tap" - Strict Inclusion/Exclusion Rules
- (Myelofibrosis, Hairy Cell Leukemia) • Prussian Blue Stain: Hemosiderin & Sideroblasts
- 1. Specimen Collection, Anatomical Sites & Anticoagulant Protocol
- Anatomical Biopsy Sites
Posterior Superior Iliac Spine (PSIS): The standard, safest, and most universally utilized anatomical site for bone marrow aspiration and trephine core biopsy in adults, children, and infants. The anterior superior iliac spine (ASIS) is an alternative in severely obese or supine immobilized patients.
Sternum: Aspiration-only site reserved strictly for adults ( > 18 years >18\text{ years} > 18 years ) when iliac crests are inaccessible.
Critical Safety Warning: Trephine core biopsy of the sternum is ABSOLUTELY CONTRAINDICATED due to the catastrophic risk of penetrating the thin posterior sternal plate into the ascending aorta, right ventricle, pericardium, or anterior mediastinum.
Tibia (Anteromedial Surface): Reserved exclusively for infants younger than 12 to 18 months 12\text{ to }18\text{ months} 12 to 18 months of age; ceases to contain active red marrow after infancy.
Specimen Fractions and Anticoagulant Requirements ASPIRATE ANTICOAGULANT ASSIGNMENT
- ┌───────────────────────────────────────────────────────────┐
- │ EDTA (Lavender Top): │
- │ • Morphologic aspirate smears, spicule squash/crush preps │
- │ • Molecular testing & FISH analysis │
- ├───────────────────────────────────────────────────────────┤
- │ Sodium Heparin (Green Top): │
- │ • Cytogenetic analysis (Karyotyping / Chromosome studies) │
- │ • Flow cytometric immunophenotyping │
- │ (Heparin preserves viable dividing cells without EDTA │
- │ induced cytoplasmic or membrane alterations) │
- └───────────────────────────────────────────────────────────┘
- Diagnostic Complementarity: Aspirate vs. Core Biopsy
Bone Marrow Aspirate: Yields free individual cells and marrow spicules/particles. Air-dried smears stained with Wright-Giemsa provide superior high-resolution cytologic detail for evaluating nuclear-cytoplasmic maturation, dysplastic changes, blast enumeration, and cytochemical staining.
Trephine Core Biopsy: Formalin-fixed, decalcified, and paraffin-embedded histological section stained with H&E. Provides definitive assessment of overall cellularity , spatial architectural relationships (erythroblastic islands, paratrabecular vs interstitial localization), granulomas, metastatic carcinoma nests, and bone trabecular remodeling.
Touch Imprints (Roll Preparations): Fresh core biopsy is gently rolled or touched along clean glass slides prior to formalin fixation.
"Dry Tap" (Punctio Sicca): Inability to aspirate marrow fluid despite correct needle placement. Common etiologies include Primary Myelofibrosis (PMF) (dense collagen/reticulin meshwork), Hairy Cell Leukemia (HCL) (fibronectin synthesis), and packed hypercellular acute leukemias. Touch preparations provide essential high-resolution single-cell cytomorphology when aspirates yield dry taps.
2. Bone Marrow Differential Count & Reference Intervals
A bone marrow differential count is performed on particle-rich aspirate smears by systematically classifying at least 300 to 500 consecutive nucleated hematopoietic cells under oil immersion ( 100 × 100\times 100 × ):
- Cell Lineage & Maturation Stage Normal Adult Reference Range (%)
- Myeloblasts 0.5 – 2.0% (Strictly < 2 − 3 % <2 - 3\% < 2 − 3% ; ≥ 20 % \ge 20\% ≥ 20% defines Acute Leukemia)
- Promyelocytes 1.0 – 4.0%
- Neutrophilic Myelocytes 5.0 – 15.0%
- Neutrophilic Metamyelocytes 10.0 – 20.0%
- Neutrophilic Bands 10.0 – 25.0%
- Segmented Neutrophils 10.0 – 25.0%
- Total Neutrophilic Series 50.0 – 70.0%
- Eosinophils & Precursors 1.0 – 4.0%
- Basophils & Precursors 0.1 – 1.0%
- Pronormoblasts (Rubriblasts) 0.5 – 1.5%
- Basophilic Normoblasts (Prorubricytes) 1.0 – 4.0%
- Polychromatophilic Normoblasts (Rubricytes) 5.0 – 15.0%
- Orthochromic Normoblasts (Metarubricytes) 5.0 – 15.0%
- Total Nucleated Erythroid Series 15.0 – 30.0%
- Lymphocytes 5.0 – 15.0% (Pediatric: up to 20–30%)
- Monocytes 0.5 – 3.0%
Plasma Cells 0.5 – 2.0% (Strictly < 3.0 % <3.0\% < 3.0% ; ≥ 10 % \ge 10\% ≥ 10% diagnostic for Plasma Cell Myeloma)
Megakaryocytes Evaluated on low power ( 10 × 10\times 10 × ): Normally 2 to 5 per low-power field (not in 500-cell count)
3. Myeloid-to-Erythroid (M:E) Ratio Calculation & Interpretation
The Myeloid-to-Erythroid (M:E) ratio expresses the quantitative numerical balance between granulocytic precursors and nucleated erythroid precursors in the bone marrow: M:E Ratio = ∑ Granulocytic / Myeloid Series (Myeloblasts through Segmented Neutrophils, Eos, Basos) ∑ Nucleated Erythroid Series (Pronormoblasts through Orthochromic Normoblasts) \text{M:E Ratio} = \frac{\sum \text{Granulocytic / Myeloid Series (Myeloblasts through Segmented Neutrophils, Eos, Basos)}}{\sum \text{Nucleated Erythroid Series (Pronormoblasts through Orthochromic Normoblasts)}} M:E Ratio = ∑ Nucleated Erythroid Series (Pronormoblasts through Orthochromic Normoblasts) ∑ Granulocytic / Myeloid Series (Myeloblasts through Segmented Neutrophils, Eos, Basos) M:E RATIO CALCULATION RULES
NUMERATOR (MYELOID LINEAGE): DENOMINATOR (ERYTHROID LINEAGE):
- [+] Myeloblasts [+] Pronormoblasts (Rubriblasts)
- [+] Promyelocytes [+] Basophilic Normoblasts (Prorubricytes)
- [+] Neutrophilic Myelocytes [+] Polychromatophilic Normoblasts (Rubricytes)
- [+] Neutrophilic Metamyelocytes [+] Orthochromic Normoblasts (Metarubricytes)
- [+] Neutrophilic Bands
- [+] Segmented Neutrophils
- [+] Eosinophils & Precursors
- [+] Basophils & Precursors
═════════════════════════════════════════════════════════════════════════════════
STRICTLY EXCLUDED FROM BOTH NUMERATOR AND DENOMINATOR:
- [X] Lymphocytes [X] Plasma Cells [X] Monocytes & Macrophages
- [X] Megakaryocytes [X] Osteoblasts [X] Osteoclasts & Stromal Cells
- Reference Intervals
Normal Adult Range: 1.5 : 1 to 3.0 : 1 1.5:1\text{ to }3.0:1 1.5 : 1 to 3.0 : 1 (Standard accepted range: 1.5 : 1 to 4.0 : 1 1.5:1\text{ to }4.0:1 1.5 : 1 to 4.0 : 1 ; mean adult average ≈ 2.5 : 1 \approx 2.5:1 ≈ 2.5 : 1 ).
- Clinical Differential Diagnosis of Altered M:E Ratios M:E RATIO INTERPRETATION
- │
- ┌──────────────────────────┴──────────────────────────┐
- ▼ ▼
- [ ELEVATED M:E RATIO (>4:1) ] [ DECREASED M:E RATIO (<1.5:1) ]
- MYELOID HYPERPLASIA: • ERYTHROID HYPERPLASIA:
- Severe Bacterial Infection / Leukemoid - Hemolytic Anemias (Compensatory)
- Chronic Myeloid Leukemia (CML) - Megaloblastic Anemia (Ineffective)
- Myeloproliferative Neoplasms (MPN) - Thalassemia Major / Intermedia
- G-CSF / GM-CSF Therapy - Polycythemia Vera / EPO Therapy
- ERYTHROID HYPOPLASIA: - Acute Blood Loss Recovery
- Pure Red Cell Aplasia (PRCA) • MYELOID HYPOPLASIA:
- Parvovirus B19 Infection - Severe Agranulocytosis
- Renal Failure (EPO Deficiency) - Drug-Induced Myelosuppression
Clinical Condition Total Marrow Cellularity Myeloid Component Erythroid Component Calculated M:E Ratio
Normal Adult Normal ( 40 − 60 % 40 - 60\% 40 − 60% ) Normal ( 50 − 70 % 50 - 70\% 50 − 70% ) Normal ( 15 − 30 % 15 - 30\% 15 − 30% ) 1.5:1 to 3.0:1
Severe Bacterial Sepsis / Leukemoid Hypercellular ( > 80 % >80\% > 80% ) Hyperplastic ( ↑ \uparrow ↑ ) Normal Elevated (6:1 to 15:1)
Chronic Myeloid Leukemia (CML) Markedly Hypercellular ( 90 − 100 % 90 - 100\% 90 − 100% ) Massive Hyperplasia ( ↑ ↑ \uparrow\uparrow ↑↑ ) Normal / Decreased Markedly Elevated (10:1 to 20:1)
Pure Red Cell Aplasia (PRCA) Normocellular / Hypocellular Normal Absent / Marked Hypoplasia ( ↓ ↓ \downarrow\downarrow ↓↓ ) Markedly Elevated (>20:1 to infinity)
Autoimmune Hemolytic Anemia Hypercellular ( > 70 % >70\% > 70% ) Normal Massive Erythroid Hyperplasia ( ↑ ↑ \uparrow\uparrow ↑↑ ) Decreased (0.3:1 to 0.8:1)
Megaloblastic Anemia Markedly Hypercellular ( 80 − 100 % 80 - 100\% 80 − 100% ) Ineffective / Dysplastic Massive Ineffective Hyperplasia ( ↑ ↑ \uparrow\uparrow ↑↑ ) Decreased (0.2:1 to 0.8:1)
Agranulocytosis Hypocellular Marked Myeloid Hypoplasia ( ↓ ↓ \downarrow\downarrow ↓↓ ) Normal Decreased (0.1:1 to 0.5:1)
Severe Aplastic Anemia Severely Hypocellular ( < 10 − 20 % <10 - 20\% < 10 − 20% ) Aplastic ( ↓ ↓ \downarrow\downarrow ↓↓ ) Aplastic ( ↓ ↓ \downarrow\downarrow ↓↓ ) Normal (Proportional pan-hypoplasia)
- 4. Assessment of Marrow Cellularity and Bone Marrow Iron
- Marrow Cellularity Estimation
Marrow cellularity represents the volumetric proportion of hematopoietic tissue relative to adipose tissue (yellow fat) evaluated on trephine core biopsy sections under low power ( 10 × 10\times 10 × ): Expected Normal Adult Cellularity (%) = ( 100 − Patient Age ) ± 10 % \text{Expected Normal Adult Cellularity (\%)} = (100 - \text{Patient Age}) \pm 10\% Expected Normal Adult Cellularity (%) = ( 100 − Patient Age ) ± 10%
Clinical Example: A 70-year-old patient has an expected cellularity of ( 100 − 70 ) ± 10 % = 30 % ± 10 % (100 - 70) \pm 10\% = 30\% \pm 10\% ( 100 − 70 ) ± 10% = 30% ± 10% (reference range: 20 % to 40 % 20\%\text{ to }40\% 20% to 40% ).
Hypercellularity: Exceeds upper age-adjusted limit ( > 80 − 90 % >80 - 90\% > 80 − 90% in MPNs, leukemias, or severe hemolytic anemias).
Hypocellularity: Below lower age-adjusted limit ( < 20 − 25 % <20 - 25\% < 20 − 25% in aplastic anemia, hypoplastic MDS, post-chemotherapy aplasia).
Prussian Blue (Perls' Reaction) Stain for Bone Marrow Iron
The Prussian blue reaction treats aspirate smears and core biopsy sections with acid ferrocyanide, which reacts with intracellular ferric iron ( F e 3 + Fe^{3+} F e 3 + ) to form insoluble ferric ferrocyanide (Prussian blue precipitate): PRUSSIAN BLUE MARROW EVALUATION
- │
- ┌───────────────────────────┴───────────────────────────┐
- ▼ ▼
- MACROPHAGE STORAGE IRON (HEMOSIDERIN) SIDEROBLAST IDENTIFICATION
- Graded 0 to 4+: • Normal Sideroblasts:
- 0: Absent (Iron Deficiency Anemia) - 30–50% of developing normoblasts
- 1+: Trace / Slightly decreased - 1 to 4 fine blue granules (Random)
- 2+: Normal / Adequate • Ring Sideroblasts (Pathologic):
- 3+: Moderately increased (ACD) - ≥5 iron granules encircling ≥1/3
- 4+: Markedly increased / Coarse clumps of the nuclear circumference
- (Hemosiderosis / Hemochromatosis) - MDS-RS (SF3B1 mutation) & Plumbism
Macrophage Hemosiderin Storage Iron: Evaluates reticuloendothelial storage reserves in marrow spicules on a standardized 0 to 4+ scale:
Grade 0 (Absent): Diagnostic of Iron Deficiency Anemia (IDA) .
Grade 2+ (Adequate / Normal): Normal physiological iron reserve.
Grade 3+ to 4+ (Markedly Increased): Characteristic of Anemia of Chronic Disease (ACD / ACI) (trapped storage iron), Sideroblastic Anemia, and systemic hemochromatosis.
Sideroblasts: Developing nucleated red blood cells containing Prussian blue-positive non-heme iron granules:
Normal Sideroblasts: Comprise 30 % to 50 % 30\%\text{ to }50\% 30% to 50% of normal marrow normoblasts, containing 1 to 4 small, fine, randomly scattered iron granules in the cytoplasm.
Ring Sideroblasts: Pathologic normoblasts defined by 5 or more siderotic iron granules encircling at least one-third ( ≥ 1 / 3 \ge 1/3 ≥ 1/3 ) of the nuclear circumference . Ultrastructurally, these granules represent iron-overloaded, swollen mitochondria hugging the nuclear membrane. Hallmark of Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS) (associated with somatic mutations in SF3B1 ) and hereditary/toxin-induced sideroblastic anemias ( A L A S 2 ALAS2 A L A S 2 mutation, lead poisoning, chronic alcohol abuse).
5. Histochemical Stains for Marrow Fibrosis Grading WHO MARROW FIBROSIS GRADING
- ┌─────────────────────────────────────────────────────────────┐
- │ MF-0: Normal: Scattered linear reticulin; no intersections │
- │ MF-1: Early: Loose network of reticulin with intersections │
- │ MF-2: Moderate: Diffuse dense reticulin network with focal │
- │ thick collagen bundles │
- │ MF-3: Advanced: Coarse collagen bundles with osteosclerosis │
- │ and new bone formation (Primary Myelofibrosis) │
- └─────────────────────────────────────────────────────────────┘
Reticulin Silver Stain (Gomori / Snook): Silver impregnation technique that stains fine reticulin (Type III collagen) fibers black. Used to grade myelofibrosis across the WHO scale (MF-0 to MF-3).
Masson Trichrome Stain: Stains dense collagen (Type I collagen) vivid blue/green. Identifies advanced, irreversible osteosclerotic collagenous fibrosis in end-stage Primary Myelofibrosis (PMF) and metastatic myelophthisic processes.